Treatment Lowers Testosterone Levels in Advanced Prostate Cancer Patients in Phase 3 Trial

Treatment Lowers Testosterone Levels in Advanced Prostate Cancer Patients in Phase 3 Trial
Foresee Pharmaceuticals has reported positive results from its Phase 3 clinical trial assessing FP-001 LMIS — a ready-to-use, testosterone-lowering treatment — in patients with advanced prostate cancer. Suppressing serum testosterone was the single-arm study’s primary goal. The active agent in FP-001 LMIS, leuprolide mesylate, is a long-acting gonadotropin-releasing hormone (GnRH) agonist. Using GnRH agents for short periods can cause testosterone levels

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *